197 related articles for article (PubMed ID: 10745556)
1. The glycoprotein IIb/IIIa receptor inhibitor (abciximab) in ST-segment elevation myocardial infarction.
Mesquita A; Baptista J; Palos J; Seabra-Gomes R
J Invasive Cardiol; 1999 Jun; 11(6):379-82. PubMed ID: 10745556
[TBL] [Abstract][Full Text] [Related]
2. Relationship between patient's risk profile and benefits in mortality from adjunctive abciximab to mechanical revascularization for ST-segment elevation myocardial infarction: a meta-regression analysis of randomized trials.
De Luca G; Suryapranata H; Stone GW; Antoniucci D; Tcheng JE; Neumann FJ; Bonizzoni E; Topol EJ; Chiariello M
J Am Coll Cardiol; 2006 Feb; 47(3):685-6. PubMed ID: 16458158
[No Abstract] [Full Text] [Related]
3. Safety and tolerability of abciximab in patients with acute myocardial infarction and failed thrombolysis.
Di Pasquale P; Cannizzaro S; Scalzo S; Maringhini G; Vitrano GM; Giubilato A; Giambanco F; Sarullo FM; Paterna S
Int J Cardiol; 2003 Dec; 92(2-3):265-70. PubMed ID: 14659863
[TBL] [Abstract][Full Text] [Related]
4. Upstream/downstream glycoprotein IIb/IIIa in non-ST-segment elevation myocardial infarction.
Ben-Yehuda O
J Am Coll Cardiol; 2006 Feb; 47(3):538-40. PubMed ID: 16458132
[No Abstract] [Full Text] [Related]
5. Role of glycoprotein IIb/IIIa-receptor inhibitors in managing ST-segment-elevation myocardial infarction.
Racine E
Am J Health Syst Pharm; 2002 Nov; 59(21 Suppl 7):S27-36. PubMed ID: 12434712
[TBL] [Abstract][Full Text] [Related]
6. Effects of abciximab as adjunctive therapy in primary percutaneous coronary intervention patients (results from the DANAMI-2 trial).
Sejersten M; Maynard C; Clemmensen P;
Acute Card Care; 2006; 8(2):75-82. PubMed ID: 16885070
[TBL] [Abstract][Full Text] [Related]
7. Glycoprotein IIb/IIIa receptor inhibitor use in unstable angina/non-ST-segment elevation myocardial infarction: an appropriate-use model for the emergency department.
Hoekstra J
J Emerg Med; 2000 Oct; 19(3 Suppl):13S-19S. PubMed ID: 11050379
[TBL] [Abstract][Full Text] [Related]
8. Effects of GP IIb/IIIa inhibitors on vascular inflammation, coronary microcirculation, and platelet function.
Kereiakes DJ
Rev Cardiovasc Med; 2006; 7 Suppl 4():S3-11. PubMed ID: 17224889
[TBL] [Abstract][Full Text] [Related]
9. Complementary clinical benefits of coronary-artery stenting and blockade of platelet glycoprotein IIb/IIIa receptors. Evaluation of Platelet IIb/IIIa Inhibition in Stenting Investigators.
Lincoff AM; Califf RM; Moliterno DJ; Ellis SG; Ducas J; Kramer JH; Kleiman NS; Cohen EA; Booth JE; Sapp SK; Cabot CF; Topol EJ
N Engl J Med; 1999 Jul; 341(5):319-27. PubMed ID: 10423466
[TBL] [Abstract][Full Text] [Related]
10. Platelet glycoprotein IIb/IIIa receptor blockade in acute myocardial infarction associated with thrombotic occlusion of the left main coronary artery.
Rechavia E; Wurzel M
Circulation; 1998 Sep; 98(12):1249-50. PubMed ID: 9743517
[No Abstract] [Full Text] [Related]
11. Abciximab and atherosclerotic heart disease: use in percutaneous coronary intervention, acute coronary syndromes and acute myocardial infarction.
Gum PA; Lincoff AM
Int J Clin Pract; 2003; 57(1):43-8. PubMed ID: 12587942
[TBL] [Abstract][Full Text] [Related]
12. Platelet glycoprotein IIb/IIIa inhibition as adjunctive therapy during primary percutaneous coronary intervention for acute ST-segment elevation myocardial infarction.
Young JJ
J Invasive Cardiol; 2005 Jun; 17(6):300-1. PubMed ID: 16003003
[No Abstract] [Full Text] [Related]
13. Platelet glycoprotein IIb/IIIa inhibition with coronary stenting for acute myocardial infarction.
Montalescot G; Barragan P; Wittenberg O; Ecollan P; Elhadad S; Villain P; Boulenc JM; Morice MC; Maillard L; Pansiéri M; Choussat R; Pinton P;
N Engl J Med; 2001 Jun; 344(25):1895-903. PubMed ID: 11419426
[TBL] [Abstract][Full Text] [Related]
14. Comparison of ST-segment resolution with combined fibrinolytic and glycoprotein IIb/IIIa inhibitor therapy versus fibrinolytic alone (data from four clinical trials).
Rebeiz AG; Johanson P; Green CL; Crater SW; Roe MT; Langer A; Giugliano RP; Lincoff AM; Newby LK; Harrington RA; Topol EJ; Califf RM; Wagner GS; Krucoff MW
Am J Cardiol; 2005 Mar; 95(5):611-4. PubMed ID: 15721101
[TBL] [Abstract][Full Text] [Related]
15. Use of glycoprotein IIb/IIIa inhibitors in invasively-treated patients with non-ST elevation acute coronary syndrome.
De Servi S; Mariani M; Vandoni P; Dellavalle A; Politi A; Poletti F; Bonizzoni E; Leoncinie M;
J Cardiovasc Med (Hagerstown); 2006 Mar; 7(3):159-65. PubMed ID: 16645379
[TBL] [Abstract][Full Text] [Related]
16. Increased morning ADP-dependent platelet aggregation persists despite dual antiplatelet therapy in patients with first ST-segment elevation myocardial infarction: Preliminary report.
Koziński M; Bielis L; Wiśniewska-Szmyt J; Sukiennik A; Grabczewska Z; Swiatkiewicz I; Ziołkowski M; Rość D; Kubica J
Cardiol J; 2008; 15(6):530-6. PubMed ID: 19039757
[TBL] [Abstract][Full Text] [Related]
17. Early administration of abciximab bolus in the emergency department improves angiographic outcome after primary PCI as assessed by TIMI frame count: results of the early ReoPro administration in myocardial infarction (ERAMI) trial.
Gabriel HM; Oliveira JA; da Silva PC; da Costa JM; da Cunha JA
Catheter Cardiovasc Interv; 2006 Aug; 68(2):218-24. PubMed ID: 16817177
[TBL] [Abstract][Full Text] [Related]
18. Use of glycoprotein IIb/IIIa inhibitors in acute coronary syndromes.
Parmar R; Stouffer GA
Am J Med Sci; 1997 Jul; 314(1):31-6. PubMed ID: 9216438
[No Abstract] [Full Text] [Related]
19. Benefits and risks of abciximab use in primary angioplasty for acute myocardial infarction: the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) trial.
Tcheng JE; Kandzari DE; Grines CL; Cox DA; Effron MB; Garcia E; Griffin JJ; Guagliumi G; Stuckey T; Turco M; Fahy M; Lansky AJ; Mehran R; Stone GW;
Circulation; 2003 Sep; 108(11):1316-23. PubMed ID: 12939213
[TBL] [Abstract][Full Text] [Related]
20. Glycoprotein IIb/IIIa receptor inhibitors in 2008: do they still have a role?
Mukherjee D; Roffi M
J Interv Cardiol; 2008 Apr; 21(2):118-21. PubMed ID: 18384343
[No Abstract] [Full Text] [Related]
[Next] [New Search]
